{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:34:48Z","timestamp":1773311688584,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1093\/jnci\/dju354","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T01:31:44Z","timestamp":1417743104000},"source":"Crossref","is-referenced-by-count":33,"title":["Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention"],"prefix":"10.1093","volume":"107","author":[{"given":"Hazel B.","family":"Nichols","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"DeRoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale P.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,12,3]]},"reference":[{"issue":"7","key":"key\n\t\t\t\t20170520213900_CIT0001","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","article-title":"Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention","volume":"95","author":"Freedman","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"9880","key":"key\n\t\t\t\t20170520213900_CIT0002","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"9336","key":"key\n\t\t\t\t20170520213900_CIT0003","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"issue":"18","key":"key\n\t\t\t\t20170520213900_CIT0004","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9122","key":"key\n\t\t\t\t20170520213900_CIT0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"issue":"9122","key":"key\n\t\t\t\t20170520213900_CIT0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)85011-3","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study","volume":"352","author":"Veronesi","year":"1998","journal-title":"Lancet"},{"issue":"23","key":"key\n\t\t\t\t20170520213900_CIT0007","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"key\n\t\t\t\t20170520213900_CIT0008","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-159-10-201311190-00718","article-title":"Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"key\n\t\t\t\t20170520213900_CIT0009","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10549-012-2089-2","article-title":"Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010","volume":"134","author":"Waters","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"key\n\t\t\t\t20170520213900_CIT0010","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archinte.161.13.1639","article-title":"Women\u2019s interest in chemoprevention for breast cancer","volume":"161","author":"Bastian","year":"2001","journal-title":"Arch Intern Med"},{"issue":"3","key":"key\n\t\t\t\t20170520213900_CIT0011","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10549-007-9614-8","article-title":"Interest in breast cancer chemoprevention among older women","volume":"108","author":"Tjia","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"key\n\t\t\t\t20170520213900_CIT0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-005-6932-6","article-title":"How should we inform women at higher risk of breast cancer about tamoxifen? An approach with a decision guide","volume":"94","author":"McKay","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"key\n\t\t\t\t20170520213900_CIT0013","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.20205","article-title":"Acceptance of tamoxifen chemoprevention by physicians and women at risk","volume":"100","author":"Tchou","year":"2004","journal-title":"Cancer"},{"issue":"18","key":"key\n\t\t\t\t20170520213900_CIT0014","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","article-title":"Validation studies for models projecting the risk of invasive and total breast cancer incidence","volume":"91","author":"Costantino","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"key\n\t\t\t\t20170520213900_CIT0015","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"key\n\t\t\t\t20170520213900_CIT0016","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer","volume":"91","author":"Gail","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"key\n\t\t\t\t20170520213900_CIT0017","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/jnci\/djm223","article-title":"Projecting individualized absolute invasive breast cancer risk in African American women","volume":"99","author":"Gail","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"key\n\t\t\t\t20170520213900_CIT0018","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/jnci\/djr154","article-title":"Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women","volume":"103","author":"Matsuno","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"key\n\t\t\t\t20170520213900_CIT0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","article-title":"Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention","volume":"93","author":"Rockhill","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"key\n\t\t\t\t20170520213900_CIT0020","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","article-title":"Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older","volume":"29","author":"Freedman","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170520213900_CIT0021","article-title":"Breast Cancer Risk Reduction Guidelines Version 1.2012 National Comprehensive Cancer Center Network"},{"key":"key\n\t\t\t\t20170520213900_CIT0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"Am Stat Assoc J"},{"issue":"25","key":"key\n\t\t\t\t20170520213900_CIT0023","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"9922","key":"key\n\t\t\t\t20170520213900_CIT0024","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"18","key":"key\n\t\t\t\t20170520213900_CIT0025","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170520213900_CIT0026","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-006-9272-2","article-title":"The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs","volume":"101","author":"Fasching","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"key\n\t\t\t\t20170520213900_CIT0027","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V","article-title":"Women\u2019s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women","volume":"92","author":"Julian-Reynier","year":"2001","journal-title":"Cancer"},{"issue":"10","key":"key\n\t\t\t\t20170520213900_CIT0028","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/cncr.20981","article-title":"Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction","volume":"103","author":"Melnikow","year":"2005","journal-title":"Cancer"},{"issue":"9","key":"key\n\t\t\t\t20170520213900_CIT0029","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1940-6207.CAPR-11-0380","article-title":"Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention","volume":"4","author":"Lin","year":"2011","journal-title":"Cancer Prev Res"},{"issue":"1","key":"key\n\t\t\t\t20170520213900_CIT0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-013-2422-4","article-title":"A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians","volume":"138","author":"Huiart","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"key\n\t\t\t\t20170520213900_CIT0031","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/1940-6207.CAPR-13-0389","article-title":"Adherence to endocrine therapy in breast cancer adjuvant and prevention settings","volume":"7","author":"Chlebowski","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"18","key":"key\n\t\t\t\t20170520213900_CIT0032","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"issue":"5","key":"key\n\t\t\t\t20170520213900_CIT0033","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1075-122X.2006.00295.x","article-title":"Predicting compliance in a breast cancer prevention trial","volume":"12","author":"Maurice","year":"2006","journal-title":"Breast J"},{"issue":"9","key":"key\n\t\t\t\t20170520213900_CIT0034","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1158\/1940-6207.CAPR-11-0172","article-title":"Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial","volume":"4","author":"Land","year":"2011","journal-title":"Cancer Prev Res"},{"key":"key\n\t\t\t\t20170520213900_CIT0035","doi-asserted-by":"crossref","first-page":"310804","DOI":"10.1155\/2012\/310804","article-title":"Accuracy of Self-Reported Breast Cancer Information among Women from the Ontario Site of the Breast Cancer Family Registry","volume":"2012","author":"Barisic","year":"2012","journal-title":"J Cancer Epidemiol"},{"issue":"21","key":"key\n\t\t\t\t20170520213900_CIT0036","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1200\/JCO.2005.03.002","article-title":"Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry","volume":"23","author":"Phillips","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"key\n\t\t\t\t20170520213900_CIT0037","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/humrep\/deh840","article-title":"Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis","volume":"20","author":"Steiner","year":"2005","journal-title":"Hum Reprod"},{"issue":"9788","key":"key\n\t\t\t\t20170520213900_CIT0038","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial","volume":"378","author":"Vaglio","year":"2011","journal-title":"Lancet"},{"issue":"1\u20133","key":"key\n\t\t\t\t20170520213900_CIT0039","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jad.2010.08.015","article-title":"Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania","volume":"129","author":"Amrollahi","year":"2011","journal-title":"J Affect Dis"},{"issue":"2","key":"key\n\t\t\t\t20170520213900_CIT0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"New Engl J Med"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/107\/1\/dju354\/17313822\/dju354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:07:55Z","timestamp":1747177675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/dju354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,3]]},"published-print":{"date-parts":[[2015,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dju354","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12,3]]}}}